- Home
- INM vs SMTI Comparison
INM vs SMTI Comparison
Compare INM & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INM | SMTI |
|---|---|---|
| Founded | 1981 | 1982 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 208.2M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | INM | SMTI |
|---|---|---|
| Price | $1.52 | $34.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 758.6K | 255.7K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $4,942,633.00 | ★ $15,586,976.00 |
| Revenue This Year | N/A | $17.31 |
| Revenue Next Year | N/A | $12.48 |
| P/E Ratio | ★ N/A | $680.00 |
| Revenue Growth | 7.50 | ★ 32.47 |
| 52 Week Low | $0.58 | $16.05 |
| 52 Week High | $2.50 | $35.70 |
Technical Indicators
Market Signals| Indicator | INM | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | N/A |
| Support Level | $1.09 | N/A |
| Resistance Level | $1.70 | N/A |
| Average True Range (ATR) | 0.18 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 5.01 | 0.00 |
Price Performance
Historical ComparisonAbout INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.